- Pfizer (PFE +1.5%) will submit an FDA new drug application for the use of its Palbociclib drug, together with Letrozole, for the "treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer."
- The decision stems from the results of Pfizer's Paloma-1 Phase 2 trial for Palbociclib/Letrozole. An NDA submission is expected in early Q3.
- Pfizer is trading higher after coming off a halt. AstraZenaca (AZN +0.4%) investors are breathing a sigh of relief.
From other sites
Video at CNBC.com (Aug 26, 2015)
Video at CNBC.com (Jul 27, 2015)
at CNBC.com (Jun 1, 2015)
at CNBC.com (May 28, 2015)
at CNBC.com (Apr 10, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs